Clinical Trials Sponsored by Anthera Pharmaceuticals

Total 20356 results

Anthera Pharmaceuticals

Completed

BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration

IgA Nephropathy

Czechia, Germany, Hong Kong, Korea, Republic of, Malaysia, Philippines, Singapore, Taiwan, Thailand, United Kingdom
Anthera Pharmaceuticals

Completed

FRANCIS-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary Syndromes (FRANCIS-ACS)

Acute Coronary Syndrome

Russian Federation, Georgia, Ukraine
Anthera Pharmaceuticals

Terminated

A Study of Varespladib Infusion in Subjects With Sickle Cell Disease. (IMPACTS-2)

Sickle Cell Disease | Vaso-occlusive Crisis

United States
Anthera Pharmaceuticals

Completed

A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321

Systemic Lupus Erythematosus

United States, Argentina, Brazil, Chile, Colombia, Hong Kong, India, Mexico, Peru, Philippines, Taiwan
Anthera Pharmaceuticals

Terminated

VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome (VISTA-16)

Acute Coronary Syndrome

United States, Australia, Canada, Czech Republic, Georgia, Germany, Hungary, India, Italy, Korea, Republic of, Lebanon, Netherlands, New Zealand, Poland, Russian Federation, Spain, Ukraine
Anthera Pharmaceuticals

Terminated

A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal Function

Renal Impairment

United States
Anthera Pharmaceuticals

Completed

Study to Assess the Metabolism and Elimination of [14C]-Labeled Varespladib Methyl in Healthy Male Subjects

Healthy Volunteers

United States
Anthera Pharmaceuticals

Completed

SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States, Hungary, Israel, Poland, Spain, Canada, Czechia
Anthera Pharmaceuticals

Completed

SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis (SIMPLICITY)

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Anthera Pharmaceuticals

Withdrawn

CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis

Systemic Lupus Erythematosus
Anthera Pharmaceuticals

Withdrawn

BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis (BIANCA-SC)

Microscopic Polyangiitis | Granulomatosis With Polyangiitis
Anthera Pharmaceuticals

Withdrawn

BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy

IgA Nephropathy
Anthera Pharmaceuticals

Terminated

Phase III ALTU-135 CP Safety Trial (DIGEST CP)

Exocrine Pancreatic Insufficiency

United States
Anthera Pharmaceuticals

Completed

Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency (DIGEST)

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Anthera Pharmaceuticals

Completed

PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus (PEARL-SC)

Systemic Lupus Erythematosus

United States, Argentina, Brazil, Chile, Colombia, Hong Kong, India, Mexico, Peru, Philippines, Taiwan
Anthera Pharmaceuticals

Completed

PLASMA 2 Trial: Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery Disease (PLASMA 2)

Coronary Artery Disease

United States
Anthera Pharmaceuticals

Completed

EASY: Extended Access to Sollpura Over Years

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States, Hungary, Israel, Poland, Spain, Czechia
Anthera Pharmaceuticals

Unknown

RESULT: Reliable, Emergent Solution Using Liprotamase Treatment

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States, Hungary, Israel, Lithuania, Poland, Spain, United Kingdom
Anthera Pharmaceuticals

Terminated

CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis

Systemic Lupus Erythematosus

Georgia
Anthera Pharmaceuticals

Completed

CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus (CHABLIS-SC1)

Systemic Lupus Erythematosus

Georgia, Belarus, Brazil, Colombia, Guatemala, Hong Kong, India, Korea, Republic of, Malaysia, Mexico, Philippines, Russian Federation, Singapore, Sri Lanka, Taiwan, Thailand
Anthera Pharmaceuticals

Withdrawn

MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP

Idiopathic Thrombocytopenic Purpura | Immune Thrombocytopenic Purpura
Anthera Pharmaceuticals

Completed

Open-Label Phase III Long-Term Safety Trial of Liprotamase (DIGEST)

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Anthera Pharmaceuticals

Completed

IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome

Sickle Cell Disease | Acute Chest Syndrome | Vaso-occlusive Crisis

United States
Anthera Pharmaceuticals

Completed

PLASMA Trial: A Dose-Response Study of A-002 In Subjects With Stable Coronary Artery Disease (PLASMA)

Coronary Artery Disease (CAD)

United States, Ukraine
Santhera Pharmaceuticals
Santhera Pharmaceuticals

Active, not recruiting

A Study to Assess Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

Canada
Santhera Pharmaceuticals

Available

Expanded Access Protocol for Boys With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United States, Canada, Israel
Santhera Pharmaceuticals

Completed

Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients (IONIA-E)

Friedreich's Ataxia

United States
Santhera Pharmaceuticals

No longer available

Expanded Access Program for Idebenone in Patients With Leber's Hereditary Optic Neuropathy Who Completed the LEROS Study (US EAP LHON)

Leber's Hereditary Optic Neuropathy
Santhera Pharmaceuticals

Terminated

Phase III Study With Idebenone in Patients With Duchenne Muscular Dystrophy (SIDEROS-E) (SIDEROS-E)

Duchenne Muscular Dystrophy

United States, Belgium, United Kingdom, Austria, France, Germany, Italy, Spain, Switzerland
Santhera Pharmaceuticals

Completed

Post Authorisation Safety Study With Raxone in LHON Patients (PAROS)

Leber's Hereditary Optic Neuropathy (LHON)

Italy, Germany, France, Austria, Greece, Netherlands
Santhera Pharmaceuticals

Completed

A Study of Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia (FRDA) Patients (MICONOS)

Friedreich's Ataxia

Netherlands, Austria, United Kingdom, Belgium, France, Germany
Santhera Pharmaceuticals

Completed

Patient Reported Outcomes in Friedreich's Ataxia Patients After Withdrawal From Treatment With Idebenone (PROTI) (PROTI)

Friedreich's Ataxia

Netherlands, Austria, Germany, United Kingdom
Santhera Pharmaceuticals

Completed

Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension)

Duchenne Muscular Dystrophy

Belgium
Santhera Pharmaceuticals

Completed

Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia (IONIA)

Friedreich's Ataxia

United States
Santhera Pharmaceuticals

Completed

Study to Assess the Efficacy and Safety of Raxone in LHON Patients (LEROS)

Leber's Hereditary Optic Neuropathy (LHON)

United States, United Kingdom, Spain, Poland, Austria, Belgium, Bulgaria, Germany, Italy, Portugal
Santhera Pharmaceuticals

Completed

Clinical Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of POL6014 in Patients With CF

Cystic Fibrosis

Germany
Santhera Pharmaceuticals

Completed

Historical Case Record Survey of Visual Acuity Data From Patients With Leber's Hereditary Optic Neuropathy (LHON)

Leber's Hereditary Optic Neuropathy (LHON)

Belgium, Netherlands, France, Germany, Norway, United Kingdom, Italy
Santhera Pharmaceuticals

Completed

A Study to Assess the Potential for Pre-systemic Inhibition of CYP3A by Idebenone Using Midazolam as a Substrate

Drug-Drug Interaction

France
Santhera Pharmaceuticals

Completed

Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD) (DELOS)

Muscular Dystrophy, Duchenne | Ambulatory Care

United States, Spain, Austria, Belgium, France, Germany, Italy, Netherlands, Sweden, Switzerland
Santhera Pharmaceuticals

Withdrawn

Study With Idebenone in Patients With Chronic Vision Loss Due to Leber's Hereditary Optic Neuropathy (LHON)

Leber's Hereditary Optic Neuropathy
Santhera Pharmaceuticals

Completed

Study to Assess Efficacy,Safety and Tolerability of Idebenone in the Treatment of Leber's Hereditary Optic Neuropathy (RHODOS)

Leber's Hereditary Optic Neuropathy

Canada, Germany, United Kingdom
Santhera Pharmaceuticals

Completed

Efficacy and Tolerability of Idebenone in Boys With Cardiac Dysfunction Associated With Duchenne Muscular Dystrophy (DELPHI)

Duchenne Muscular Dystrophy (DMD)

Belgium
Santhera Pharmaceuticals

No longer available

Expanded Access Program for Idebenone in Participants With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

United States
Santhera Pharmaceuticals

Terminated

A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid Steroids (SIDEROS)

Duchenne Muscular Dystrophy (DMD)

United States, Spain, Netherlands, Sweden, Germany, France, Belgium, United Kingdom, Italy, Ireland, Switzerland, Austria, Bulgaria, Hungary, Israel
Santhera Pharmaceuticals

Completed

Congenital Muscular Dystrophy Ascending Multiple Dose Cohort Study Analyzing Pharmacokinetics at Three Dose Levels In Children and Adolescents With Assessment of Safety and Tolerability of Omigapil (CALLISTO) (CALLISTO)

Congenital Muscular Dystrophy

United States
Santhera Pharmaceuticals

Completed

Long-Term Safety and Tolerability of Idebenone in Friedreich's Ataxia Patients (MICONOS Extension)

Freidreich's Ataxia

Germany, Netherlands, France, Austria, Belgium
Santhera Pharmaceuticals

Completed

RHODOS Follow-up Single-visit Study (RHODOS-OFU)

Leber's Hereditary Optic Neuropathy

Canada, Germany, United Kingdom
Anthera Pharmaceuticals
Cystic Fibrosis Foundation

Completed

Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency

Cystic Fibrosis | Pancreatic Insufficiency

United States
Othera Pharmaceuticals

Completed

Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma

Ocular Hypertension | Glaucoma, Open-Angle

United States
Othera Pharmaceuticals

Terminated

Study of OT-551 Eye Drops to Prevent or Delay Progression of Nuclear Cataracts Following Vitreous Removal

Epiretinal Membrane | Macular Hole

United States

Clinical Trials Sponsored by Anthera Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in India

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations